Literature DB >> 9668550

Treatment of iron overload in the "ex-thalassemic". Report from the phlebotomy program.

E Angelucci1, P Muretto, G Lucarelli, M Ripalti, D Baronciani, B Erer, M Galimberti, M Annibali, C Giardini, D Gaziev, S Rapa, P Polchi.   

Abstract

After successful marrow transplantation (BMT) iron overload remains an important cause of morbidity in Thalassemia. After BMT, patients have normal erythropoiesis capable of producing a hyperplastic response to phlebotomy so that this procedure can be contemplated as a method of mobilizing iron from overloaded tissues. Forty-one patients (mean age 16 +/- 2.9 years) with prolonged follow-up (range 2-7 years) after BMT were submitted to a moderate intensity phlebotomy program (6 ml/kg blood withdrawal at 14-day intervals) to reduce iron overload. Values are expressed as mean +/- SD or as median with a range (25th-75th percentile). Serum ferritin decreased from 2,587 (2,129-4,817) to 280 (132-920) micrograms/l (p < 0.0001), total transferrin increased from 2.34 +/- 0.37 to 2.9 +/- 0.66 g/l (p = 0.0001), transferrin saturation decreased from 90% +/- 14% to 39% +/- 34% (p < 0.0001). Liver iron concentration evaluated on liver biopsy specimens decreased from 20.8 (15.5-28.1) to 3 (0.9-14.6) mg/g dry weight (p < 0.0001). Alanine amino-transaminase from 5.2 +/- 3.4 to 1.6 +/- 1.2 (p < 0.0001) times the upper level of normality. The histological grading for chronic hepatitis (Histology Activity Index) decreased from 4.2 +/- 2.4 to 2.3 +/- 1.8 (p < 0.0001). Phlebotomy is a safe, efficient, and widely applicable method to decrease iron overload in "ex-thalassemic."

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9668550     DOI: 10.1111/j.1749-6632.1998.tb10485.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

Review 1.  Liver iron content determination by magnetic resonance imaging.

Authors:  Konstantinos Tziomalos; Vassilios Perifanis
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

2.  National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines.

Authors:  Michael A Pulsipher; Roderick Skinner; George B McDonald; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Clarisa Gracia; Anna Petryk; Smita Bhatia; Nancy Bunin; Michael L Nieder; Christopher C Dvorak; Lillian Sung; Jean E Sanders; Joanne Kurtzberg; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2012-01-14       Impact factor: 5.742

3.  National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction.

Authors:  Michael L Nieder; George B McDonald; Aiko Kida; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Michael A Pulsipher; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-01       Impact factor: 5.742

Review 4.  Optimal management strategies for chronic iron overload.

Authors:  James C Barton
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Myocardial and hepatic T2* magnetic resonance evaluation in ex-thalassemic patients after bone-marrow transplantation.

Authors:  Sophie Mavrogeni; Efstathios D Gotsis; Eleni Berdousi; Vasilios Ladis; Dimitrios Verganelakis; Panagiotis Toulas; Dennis V Cokkinos
Journal:  Int J Cardiovasc Imaging       Date:  2007-01-19       Impact factor: 2.357

Review 6.  Al-hijamah and oral honey for treating thalassemia, conditions of iron overload, and hyperferremia: toward improving the therapeutic outcomes.

Authors:  Salah Mohamed El Sayed; Hussam Baghdadi; Ashraf Abou-Taleb; Hany Salah Mahmoud; Reham A Maria; Nagwa S Ahmed; Manal Mohamed Helmy Nabo
Journal:  J Blood Med       Date:  2014-10-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.